病原感染在自身免疫性肝病发生发展中的作用

张海萍; 闫惠平; 陈德喜; 马迎民

doi:10.3969/j.issn.1001-5256.2022.04.004

病原感染在自身免疫性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2022.04.004

首都医科大学附属北京佑安医院临检中心，北京市肝病研究所，北京 100069

基金项目:

北京市属医学科研院所公益发展改革试点项目 (Jingyiyan 2021-10);

首都医科大学附属北京佑安医院2021年院内中青年人才孵育项目(青年创新类) (YNKTQN2021004)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：张海萍负责收集资料分析并撰写论文；闫惠平负责写作设计、思路指导及论文修改并最后定稿；陈德喜和马迎民负责论文审阅。

详细信息

通信作者:
闫惠平，yhp503@126.com

计量
- 文章访问数: 600
- HTML全文浏览量: 168
- PDF下载量: 99
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-04
- 录用日期: 2022-02-17
- 出版日期: 2022-04-20

The role of pathogen infections in the development and progression of autoimmune liver diseases

Center of Clinical Laboratory, Beijing YouAn Hospital, Capital Medical University & Beijing Institute of Hepatology, Beijing 100069, China

Research funding:

Pilot Project of Public Welfare Development and Reform of Beijing Municipal Medical Research Institutes (Jingyiyan 2021-10);

Young and Middle-aged Talent Incubation Project in the Hospital of Beijing YouAn Hospital, Capital Medical University, 2021 (Youth Innovation) (YNKTQN2021004)

More Information

Corresponding author: YAN Huipng, yhp503@126.com(ORCID: 0000-0002-1787-0067)

摘要

摘要: 自身免疫性肝病(AILD)的病因和发病机制研究一直是领域内的研究热点。病原体感染可参与诱发机体的自身免疫反应，常常成为免疫性疾病的关键致病因素。本文基于文献数据和作者临床经验，将从分子模拟机制等方面对病原感染在AILD的发生和发展中的作用及其影响进行简单介绍，以助更深入地了解AILD的发病机制。
- 病原 /
- 自身免疫性肝病 /
- 分子模拟 /
- 病理过程
Abstract: The etiology and pathogenesis of autoimmune liver diseases has always been a hot area of research. Pathogen infections can elicit an autoimmune response and often become the key pathogenic factor of immune diseases. Based on the literature data and the author's clinical experience, this review will briefly introduce the role and influence of pathogen infections in the development and progression of autoimmune liver diseases from the aspects such as molecular mimicry mechanism, in order to further understand the pathogenesis of autoimmune liver diseases.
- Noxae /
- Autoimmune Liver Disease /
- Molecular Mimicry /
- Pathologic Processes

HTML全文

表 1 人PDC-E2 155-1851^*的分子模拟和免疫优势表位

Table 1. Molecular mimicry and immunodominant epitopes of human PDC-E2 155-1851^*

人类PDC-E2	KVGEKLSEGDLLAEIETDK^*ATIGFEVQEEGY
B淋巴细胞	KVGEKLSEGDLLAEIETDK^*ATIGFEVQEEGY
CD4⁺T淋巴细胞	KVGEKLSEGDLLAEIETDK^*ATIGFEVQEEGY
CD8⁺T淋巴细胞	KVGEKLSEGDLLAEIETDK^*ATIGFEVQEEGY
E. coli PDC-E2 2^**	K-G-----L-EIETDK-----G-
Novosphingobium aromaticivorans	-----GD-LAEIETDKAT--FE---EG-
PDC-E2
注: K为硫辛酸的附着位点¹⁷³lysine(赖氮酸)；横线部分为每种细胞识别的表位； * ExDK序列存在于人源和大肠杆菌PDC-E2中。

下载: 导出CSV

参考文献(40)

[1]	CZAJA AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions[J]. World J Gastroenterol, 2019, 25(45): 6579-6606. DOI: 10.3748/wjg.v25.i45.6579.
[2]	TANAKA A, LEUNG P, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195(1): 25-34. DOI: 10.1111/cei.13198.
[3]	ROWLEY D, JENKIN CR. Antigenic cross-reaction between host and parasite as a possible cause of pathogenicity[J]. Nature, 1962, 193: 151-154. DOI: 10.1038/193151a0.
[4]	DAMIAN RT. Molecular mimicry in biological adaptation[J]. Science, 1965, 147(3660): 824. DOI: 10.1126/science.147.3660.824-b.
[5]	FLOREANI A, LEUNG PS, GERSHWIN ME. Environmental basis of autoimmunity[J]. Clin Rev Allergy Immunol, 2016, 50(3): 287-300. DOI: 10.1007/s12016-015-8493-8.
[6]	AGMON-LEVIN N, PAZ Z, ISRAELI E, et al. Vaccines and autoimmunity[J]. Nat Rev Rheumatol, 2009, 5(11): 648-652. DOI: 10.1038/nrrheum.2009.196.
[7]	ANG CW, JACOBS BC, LAMAN JD. The Guillain-Barré syndrome: A true case of molecular mimicry[J]. Trends Immunol, 2004, 25(2): 61-66. DOI: 10.1016/j.it.2003.12.004.
[8]	KOGA M, GILBERT M, LI J, et al. Complex of GM1- and GD1a-like lipo-oligosaccharide mimics GM1b, inducing anti-GM1b antibodies[J]. PLoS One, 2015, 10(4): e0124004. DOI: 10.1371/journal.pone.0124004.
[9]	KIRVAN CA, GALVIN JE, HILT S, et al. Identification of streptococcal m-protein cardiopathogenic epitopes in experimental autoimmune valvulitis[J]. J Cardiovasc Transl Res, 2014, 7(2): 172-181. DOI: 10.1007/s12265-013-9526-4.
[10]	ZHANG Y, XIAO M, ZHANG S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19[J]. N Engl J Med, 2020, 382(17): e38. DOI: 10.1056/NEJMc2007575.
[11]	MIELI-VERGANI G, VERGANI D, CZAJA AJ, et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4: 18017. DOI: 10.1038/nrdp.2018.17.
[12]	MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
[13]	ZACHOU K, RIGOPOULOU E, DALEKOS GN. Autoantibodies and autoantigens in autoimmune hepatitis: Important tools in clinical practice and to study pathogenesis of the disease[J]. J Autoimmune Dis, 2004, 1(1): 2. DOI: 10.1186/1740-2557-1-2.
[14]	FERRI S, MURATORI L, LENZI M, et al. HCV and autoimmunity[J]. Curr Pharm Des, 2008, 14(17): 1678-1685. DOI: 10.2174/138161208784746824.
[15]	MURATORI P, MURATORI L, VERUCCHI G, et al. Non-organ-specific autoantibodies in children with chronic hepatitis C: Clinical significance and impact on interferon treatment[J]. Clin Infect Dis, 2003, 37(10): 1320-1326. DOI: 10.1086/379018.
[16]	HAN Y, YAN HP, LIAO HY, et al. Clinical value of anti-liver/kidney microsomal-1 antibody in patients with liver disease[J]. Chin J Hepatol, 2017, 25(11): 852-857. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.010. 韩莹, 闫惠平, 廖慧钰, 等. 抗肝肾微粒体抗体在肝病患者中的临床意义评价[J]. 中华肝脏病杂志, 2017, 25(11): 852-857. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.010.
[17]	MARCEAU G, LAPIERRE P, BÉLAND K, et al. LKM1 autoantibodies in chronic hepatitis C infection: A case of molecular mimicry?[J]. Hepatology, 2005, 42(3): 675-682. DOI: 10.1002/hep.20816.
[18]	FERRI S, MURATORI L, QUARNETI C, et al. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C[J]. J Hepatol, 2009, 50(6): 1093-1101. DOI: 10.1016/j.jhep.2009.02.020.
[19]	GREGORIO GV, CHOUDHURI K, MA Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection[J]. Clin Exp Immunol, 2003, 133(3): 404-413. DOI: 10.1046/j.1365-2249.2003.02229.x.
[20]	VENTO S, GAROFANO T, DI PERRI G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals[J]. Lancet, 1991, 337(8751): 1183-1187. DOI: 10.1016/0140-6736(91)92858-y.
[21]	YAN HP, JIA JD. Autoimmune liver disease[M]. Beijing: People's Medical Publishing House, 2018. 闫惠平, 贾继东. 自身免疫性肝脏疾病[M]. 北京: 人民卫生出版社, 2018.
[22]	RIGOPOULOU EI, SMYK DS, MATTHEWS CE, et al. Epstein-barr virus as a trigger of autoimmune liver diseases[J]. Adv Virol, 2012, 2012: 987471. DOI: 10.1155/2012/987471.
[23]	CHRISTEN U, HINTERMANN E. Pathogens and autoimmune hepatitis[J]. Clin Exp Immunol, 2019, 195(1): 35-51. DOI: 10.1111/cei.13203.
[24]	ZELLOS A, SPOULOU V, ROMA-GIANNIKOU E, et al. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: Art of facts or an artifact?[J]. Ann Hepatol, 2013, 12(1): 147-151.
[25]	MANNS MP, GRIFFIN KJ, SULLIVAN KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450ⅡD6, a cytochrome P-450 monooxygenase[J]. J Clin Invest, 1991, 88(4): 1370-1378. DOI: 10.1172/JCI115443.
[26]	HAGEL S, BRUNS T, HERRMANN A, et al. Autoimmune hepatitis in an HIV-infected patient: An intriguing association[J]. Int J STD AIDS, 2012, 23(6): 448-450. DOI: 10.1258/ijsa.2009.009337.
[27]	FLOREANI A, LEUNG PS, GERSHWIN ME. Environmental basis of autoimmunity[J]. Clin Rev Allergy Immunol, 2016, 50(3): 287-300. DOI: 10.1007/s12016-015-8493-8.
[28]	BURROUGHS AK, ROSENSTEIN IJ, EPSTEIN O, et al. Bacteriuria and primary biliary cirrhosis[J]. Gut, 1984, 25(2): 133-137. DOI: 10.1136/gut.25.2.133.
[29]	FLOREANI A, BASSENDINE MF, MITCHISON H, et al. No specific association between primary biliary cirrhosis and bacteriuria?[J]. J Hepatol, 1989, 8(2): 201-207. DOI: 10.1016/0168-8278(89)90008-1.
[30]	CORPECHOT C, CHRÉTIEN Y, CHAZOUILLÈRES O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis[J]. J Hepatol, 2010, 53(1): 162-169. DOI: 10.1016/j.jhep.2010.02.019.
[31]	GERSHWIN ME, SELMI C, WORMAN HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients[J]. Hepatology, 2005, 42(5): 1194-1202. DOI: 10.1002/hep.20907.
[32]	PARIKH-PATEL A, GOLD EB, WORMAN H, et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states[J]. Hepatology, 2001, 33(1): 16-21. DOI: 10.1053/jhep.2001.21165.
[33]	PRINCE MI, DUCKER SJ, JAMES OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations[J]. Gut, 2010, 59(4): 508-512. DOI: 10.1136/gut.2009.184218.
[34]	CORPECHOT C, CHRÉTIEN Y, CHAZOUILLÈRES O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis[J]. J Hepatol, 2010, 53(1): 162-169. DOI: 10.1016/j.jhep.2010.02.019.
[35]	SHIMODA S, HARADA K, NIIRO H, et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis[J]. Hepatology, 2011, 53(4): 1270-1281. DOI: 10.1002/hep.24194.
[36]	BJÖRKLAND A, FESTIN R, MENDEL-HARTVIG I, et al. Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer cells and recruitment of primed memory T cells[J]. Hepatology, 1991, 13(6): 1106-1111. DOI: 10.1002/hep.1840130617.
[37]	van de WATER J, ANSARI A, PRINDIVILLE T, et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis[J]. J Exp Med, 1995, 181(2): 723-733. DOI: 10.1084/jem.181.2.723.
[38]	FREDRICKSON JK, BALKWILL DL, DRAKE GR, et al. Aromatic-degrading Sphingomonas isolates from the deep subsurface[J]. Appl Environ Microbiol, 1995, 61(5): 1917-1922. DOI: 10.1128/aem.61.5.1917-1922.1995.
[39]	TAKEUCHI M, HAMANA K, HIRAISHI A. Proposal of the genus Sphingomonas sensu stricto and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of phylogenetic and chemotaxonomic analyses[J]. Int J Syst Evol Microbiol, 2001, 51(Pt 4): 1405-1417. DOI: 10.1099/00207713-51-4-1405.
[40]	MANFREDO VIEIRA S, HILTENSPERGER M, KUMAR V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359(6380): 1156-1161. DOI: 10.1126/science.aar7201.